TransGenic Group

TransGenic Group Pre-Tax Margin

The Pre-Tax Profit Margin of TransGenic Group (2342.T) as of Nov 11, 2026 is -1.57 %. In the previous year, Pre-Tax Profit Margin was -5.20 % — a change of -69.71% (higher).

Pre-Tax Margin

-1.57 %

YoY

-69.71%

Last updated:

Pre-Tax Profit Margin of TransGenic Group is 2026 -1.57 % . Pre-Tax Profit Margin of TransGenic Group was 2025 -5.20 % . It decreases by -69.71% higher compared to the previous year.

The TransGenic Group Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2019
2.34 JPY
Jan 1, 2020
-2.26 JPY
Jan 1, 2021
6.29 JPY
Jan 1, 2022
22.01 JPY
Jan 1, 2023
-2.90 JPY
Jan 1, 2024
0.33 JPY
Jan 1, 2025
-5.20 JPY
Jan 1, 2026
-1.57 JPY
The TransGenic Group Pre-Tax Margin history
YEARPre-Tax MarginYoY
-1.57 %-69.71%
-5.20 %-1,678.49%
0.33 %-111.34%
-2.90 %-113.19%
22.01 %+249.65%
6.29 %-378.47%
-2.26 %-196.63%
2.34 %+482.51%
0.40 %-88.72%
3.56 %+329.79%
0.83 %+72.55%
0.48 %-107.84%
-6.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Pre-Tax Profit Margin of TransGenic Group is -1.57 % in 2026.

Pre-Tax Profit Margin of TransGenic Group changed from -5.20 % to -1.57 %, representing a -69.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's TransGenic Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — TransGenic Group

All Key Metrics — TransGenic Group